Abstract 1178
Background
Based on recommendations from several agencies, including the European Society for Medical Oncology, palliative care (PC) services are increasingly recognised as an essential part of oncology care. However, the implementation of integration of oncology and palliative care (IOP) seems to be evolving slowly and detailed progress of IOP remain unclear. This was a cross-sectional nationwide survey to clarify the current status of IOP in Japan.
Methods
We performed comparison between designated cancer hospitals (DCHs) and non-designated cancer hospitals (non-DCHs), since considerable number of patients in Japan are receiving cancer treatment at non-DCHs. We distributed the questionnaire to executives or directors of oncology departments at cancer hospitals in November 2017 and sent a reminder mail later. Our questionnaire was developed based on indicators of IOP with international consensus. We conducted descriptive statistics, t-tests and Cochrane-Armitage trend tests where appropriate. To adjust the difference of inpatient beds scale, estimates at non-DCHs were weighted by the distribution of inpatient beds at DCHs.
Results
Among the 399 DCHs and 478 non-DCHs that were surveyed, 269 (67%) and 259 (54%) responded, respectively. DCHs had significantly more PC resources than non-DCHs did (e.g. both full-time physicians and nurses on a PC team, 53% vs. 14% (p < 0.001); the availability of outpatient PC service ≥ 3days per week, 48% vs. 21% (p < 0.001)). Clinical tools for PC services were well equipped (e.g. symptom management guidelines, 89% vs. 79% (p = 0.238); PC referral criteria, 72% vs. 59% (p = 0.077)). However, strategies to identify suitable patients for PC referral seemed to be undeveloped (e.g. clinical care pathways, 17% vs. 5% (p < 0.001); referral using time trigger, 9% vs 8% (p = 0.358); referral using needs trigger, 31% vs. 20% (p = 0.820)). Mutual rotation training for both oncology and PC fellows and research opportunities on IOP were limited.
Conclusions
Non-DCHs face a severe lack of PC resources, whereas DCHs might have relatively more resources to enhance IOP. Both education and research opportunities for IOP were limited. Further research is warranted to identify specific barriers to and facilitators for implementation of IOP.
Clinical trial identification
Legal entity responsible for the study
Graduate School of Medicine, Kyoto University.
Funding
Ministry of Health Labor and Welfare in Japan (Health Labor Science Research Grant).
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract